BMX Stock Overview
BioMaxima S.A. manufactures and distributes microbiological media, reagents, and equipment for in vitro diagnostics in Poland.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 1/6 |
| Financial Health | 4/6 |
| Dividends | 1/6 |
BioMaxima S.A. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | zł15.35 |
| 52 Week High | zł27.80 |
| 52 Week Low | zł12.16 |
| Beta | -2.29 |
| 1 Month Change | 14.90% |
| 3 Month Change | -5.83% |
| 1 Year Change | -38.48% |
| 3 Year Change | -57.29% |
| 5 Year Change | 226.60% |
| Change since IPO | 94.30% |
Recent News & Updates
Recent updates
Returns On Capital Are Showing Encouraging Signs At BioMaxima (WSE:BMX)
Sep 07
BioMaxima (WSE:BMX) Seems To Use Debt Quite Sensibly
Mar 07We Think BioMaxima (WSE:BMX) Might Have The DNA Of A Multi-Bagger
Feb 02BioMaxima (WSE:BMX) Knows How To Allocate Capital Effectively
Sep 06We Think BioMaxima (WSE:BMX) Can Stay On Top Of Its Debt
Jun 04Does BioMaxima (WSE:BMX) Have A Healthy Balance Sheet?
Feb 18Are BioMaxima's (WSE:BMX) Statutory Earnings A Good Guide To Its Underlying Profitability?
Jan 14
Shareholder Returns
| BMX | PL Medical Equipment | PL Market | |
|---|---|---|---|
| 7D | 8.1% | -0.07% | -3.1% |
| 1Y | -38.5% | -2.2% | 26.2% |
Return vs Industry: BMX underperformed the Polish Medical Equipment industry which returned -2.2% over the past year.
Return vs Market: BMX underperformed the Polish Market which returned 26.2% over the past year.
Price Volatility
| BMX volatility | |
|---|---|
| BMX Average Weekly Movement | 5.8% |
| Medical Equipment Industry Average Movement | 4.8% |
| Market Average Movement | 5.1% |
| 10% most volatile stocks in PL Market | 9.7% |
| 10% least volatile stocks in PL Market | 3.1% |
Stable Share Price: BMX has not had significant price volatility in the past 3 months.
Volatility Over Time: BMX's weekly volatility (6%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1997 | 115 | Lukasz Urban | www.biomaxima.com |
BioMaxima S.A. manufactures and distributes microbiological media, reagents, and equipment for in vitro diagnostics in Poland. Its primary products include analyzers and diagnostic reagents for testing the biochemical parameters of blood and other body fluids; systems for the determination of drug resistance of microorganisms; quick diagnostic tests for detecting infectious diseases, cancer markers, heart attack markers, and addictive substances and readers; urine analysis systems; hematology analyzers and reagents; ionselective analyzers and reagents; reagents and immunological analyzers of cardiac markers; glucometers for professional use; and analyzers for gasometric tests and critical blood parameters tests. The company also provides surfaces and air controls; antibiotics discs and MIC strips; and chromogenic, dehydrated, and prepared culture media; additives and supplements for media; microbank microorganism storage systems; and veterinary products.
BioMaxima S.A. Fundamentals Summary
| BMX fundamental statistics | |
|---|---|
| Market cap | zł64.36m |
| Earnings (TTM) | zł807.00k |
| Revenue (TTM) | zł46.79m |
79.8x
P/E Ratio1.4x
P/S RatioIs BMX overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| BMX income statement (TTM) | |
|---|---|
| Revenue | zł46.79m |
| Cost of Revenue | zł28.31m |
| Gross Profit | zł18.48m |
| Other Expenses | zł17.67m |
| Earnings | zł807.00k |
Last Reported Earnings
Sep 30, 2023
Next Earnings Date
Apr 30, 2024
| Earnings per share (EPS) | 0.19 |
| Gross Margin | 39.49% |
| Net Profit Margin | 1.72% |
| Debt/Equity Ratio | 17.0% |
How did BMX perform over the long term?
See historical performance and comparison